Cullen Frost Bankers Inc. Has $88.49 Million Holdings in AbbVie Inc. $ABBV

Cullen Frost Bankers Inc. trimmed its stake in AbbVie Inc. (NYSE:ABBV) by 3.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 382,178 shares of the company’s stock after selling 14,047 shares during the period. AbbVie comprises about 1.0% of Cullen Frost Bankers Inc.’s investment portfolio, making the stock its 23rd biggest position. Cullen Frost Bankers Inc.’s holdings in AbbVie were worth $88,489,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in ABBV. Whittier Trust Co. of Nevada Inc. lifted its stake in shares of AbbVie by 1.8% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 104,375 shares of the company’s stock valued at $24,414,000 after buying an additional 1,870 shares during the period. CIBC Asset Management Inc increased its stake in AbbVie by 0.8% during the third quarter. CIBC Asset Management Inc now owns 320,907 shares of the company’s stock valued at $74,299,000 after acquiring an additional 2,466 shares during the period. TFR Capital LLC. raised its holdings in AbbVie by 5.3% in the 3rd quarter. TFR Capital LLC. now owns 16,399 shares of the company’s stock valued at $3,797,000 after acquiring an additional 825 shares in the last quarter. BLB&B Advisors LLC lifted its position in shares of AbbVie by 0.3% in the 3rd quarter. BLB&B Advisors LLC now owns 87,556 shares of the company’s stock worth $20,273,000 after acquiring an additional 269 shares during the period. Finally, Sagespring Wealth Partners LLC grew its holdings in shares of AbbVie by 12.4% during the 3rd quarter. Sagespring Wealth Partners LLC now owns 38,051 shares of the company’s stock worth $8,810,000 after purchasing an additional 4,192 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

Analyst Ratings Changes

ABBV has been the subject of a number of recent research reports. Citigroup cut their target price on AbbVie from $240.00 to $235.00 and set a “neutral” rating for the company in a research note on Monday, November 3rd. Scotiabank began coverage on shares of AbbVie in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price target on the stock. Wall Street Zen downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 3rd. UBS Group reissued a “neutral” rating on shares of AbbVie in a research note on Tuesday, January 13th. Finally, Bank of America increased their price target on shares of AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $248.11.

AbbVie Trading Up 0.5%

NYSE:ABBV opened at $219.21 on Friday. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The firm has a 50 day moving average of $225.60 and a 200-day moving average of $217.41. The stock has a market capitalization of $387.42 billion, a P/E ratio of 166.07, a price-to-earnings-growth ratio of 0.90 and a beta of 0.36.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The business had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. During the same period in the prior year, the company earned $3.00 EPS. AbbVie’s revenue for the quarter was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio is 524.24%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.